Esbriet (pirfenidone) can improve survival rates of idiopathic pulmonary fibrosis (IPF) patients by 30 percent, a real-world retrospective analysis shows. The study, “Pirfenidone improves survival in IPF: results from a real-life study,” was published in the journal BMC Pulmonary Medicine. Genentech’s Esbriet is an approved…
News
Preclinical data show that treatment with Nuformix’s investigational candidates within the NXP002 program can prevent fibrosis progression with enhanced efficiency compared to the current standard of care, the company announced. The study, conducted in collaboration with researchers at Newcastle University, U.K., revealed that the new therapeutic agents…
Idiopathic pulmonary fibrosis (IPF) patients experience a significant decline in quality of life and worse symptom burden during the last months of life, a real-world study shows. The Finland-based study, “Marked deterioration in the quality of life of patients with idiopathic pulmonary fibrosis during the last…
RXC006, an oral treatment candidate for idiopathic pulmonary fibrosis (IPF) and other types of fibrosis, was seen to ease lung scarring in a mouse model of IPF, its developer, Redx Pharma, has announced. The investigative inhibitor is also reported to work favorably in human lung fibroblasts grown in the laboratory.
Middle-age adults with reduced respiratory function have up to a 27% higher risk of developing dementia or cognitive impairment later in life, a study suggests. This risk pattern is even more pronounced in patients with restrictive lung diseases such as idiopathic pulmonary fibrosis (IPF), according to the study, titled “…
A herbal extract derived from a product used in Korean traditional medicine may be a potential alternative treatment for idiopathic pulmonary fibrosis (IPF), a mouse study suggests. The herbal extract was found to reduce inflammation and markers of lung fibrosis in a mouse model of PF…
Pulmonary fibrosis significantly increases the risk of severe pneumonitis (inflammation of lung tissue) among patients with lung cancer who were treated with Opdivo or Keytruda, a retrospective study suggests. The study “Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A…
Reduced levels of decorin proteins in the blood may be linked to a lower risk of death among patients with idiopathic pulmonary fibrosis (IPF) who have experienced acute exacerbations, researchers suggest. Their findings were reported in the study, “Serum decorin is a potential prognostic biomarker in…
Bridge Biotherapeutics filed an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) to start a Phase 1 trial of its idiopathic pulmonary fibrosis (IPF) treatment candidate BBT-877 in January. BBT-877 is an inhibitor of the enzyme autotaxin (ATX). This enzyme is relevant…
Evidence that the IGFBP-5 protein contributes to the development of pulmonary fibrosis was supported by new research finding that its higher-than-normal levels in people with fibrotic disease help to drive other pro-fibrotic proteins and factors. The study, “IGFBP-5 Promotes Fibrosis via Increasing Its Own Expression and That…
